AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020
Stock Information for AIM ImmunoTech Inc.
Loading
Please wait while we load your information from QuoteMedia.